06
Dec
Biocon, the Bengaluru-based biopharmaceutical company, has announced that it will fully merge Biocon Biologics Ltd (BBL) into Biocon Ltd, making BBL a wholly owned subsidiary. Founder and executive chairperson Kiran Mazumdar-Shaw described the move as value-enhancing for investors and said the unified organisation will be better equipped to meet patients’ needs, particularly in diabetes care. Explaining the rationale, she noted that markets had consistently undervalued both entities, partly due to BBL’s earlier debt load, which would have hindered a successful IPO. She highlighted that BBL’s debt-to-EBITDA ratio has fallen from 4.3 in 2020 to 2.5 now, and is expected to…
